Atypical Hemolytic Syndrome //free\\ Jun 2026

End of Paper

Atypical HUS represents a paradigm in precision medicine: a rare disease defined by a specific molecular lesion (complement dysregulation) treated by a targeted biologic. The introduction of C5 inhibitors has reduced ESRD rates from >50% to <10% in the first year after diagnosis. However, significant challenges remain: (1) High drug costs (€300,000–€500,000/year per patient) limit global access; (2) Optimal duration of therapy is unknown; (3) Prevention of meningococcal infection remains imperfect; (4) Genetic testing is underutilized in many regions, leading to misdiagnosis as TTP or secondary TMA. atypical hemolytic syndrome

Because aHUS is so rare, it is often misdiagnosed. If you or a loved one has unexplained kidney failure paired with anemia, ask your specialist about aHUS. Early diagnosis saves kidneys, and it saves lives. End of Paper Atypical HUS represents a paradigm

Before 2011, plasma exchange (to remove mutant FH/autoantibodies) and plasma infusion (to supply functional FH) were first-line. However, response was incomplete (30-50% ESRD/death), and PEX is poorly tolerated in children and vascular-access dependent. Because aHUS is so rare, it is often misdiagnosed

💡 Early intervention is critical. Because aHUS can cause permanent organ damage within days of the first "flare," rapid diagnosis and the immediate start of complement-inhibitor therapy are essential for saving kidney function. If you are looking for more specific details, I can: